AndreaBozzo/ceres-open-data-index huggingface dataset:
Architectural services, summary statistics, by North American Industry Classification System (NAICS), inactive

This table contains 225 series, with data for years 1997 - 2012 (not all combinations necessarily have data for all years), and was last released on 2015-09-11. This table contains data described by the following dimensions (Not all combinations are available): Geography (15 items: Canada; Newfoundland and Labrador; Prince Edward Island; Nova Scotia; ...), North American Industry Classification System (NAICS) (3 items: Architectural services and landscape architectural services; Architectural services; Landscape architectural services), Summary statistics (5 items: Operating revenue; Operating expenses; Salaries, wages and benefits; Operating profit margin; ...).

Organization: Statistics Canada | Statistique Canada
What We Heard Report: HIV non-disclosure public consultation

The Government of Canada is reviewing the criminal law on HIV non-disclosure and sought feedback from the Canadian public through an online consultation. Participants were invited to share their views on possible criminal law reforms related to HIV non-disclosure. This consultation is one of the commitments made by the federal government in Canada’s first Federal 2SLGBTQI+ Action Plan, launched in August 2022.

Organization: Department of Justice Canada | Ministère de la Justice Canada
Plans to expand or restructure business or organization or acquire other businesses or organizations over the next 12 months, third quarter of 2022

<p>Plans for the business or organization to expand or restructure, or to acquire or invest in other businesses or organizations over the next 12 months, by North American Industry Classification System (NAICS), business employment size, type of business, business activity and majority ownership, third quarter of 2022.<br>
</p>


Organization: Statistics Canada | Statistique Canada
Extent and growth of contiguously settled areas

Measures of settled area extent and expansion based on Earth observation-derived land cover data. Variables include extent and growth of the contiguously settled area (CSA) and growth of built-up and artificial surfaces within surrounding buffer areas. CSA boundaries are created for Statistics Canada population centres with a population larger than 5,000 people or those located within a census metropolitan area or census agglomeration.<br>

Organization: Statistics Canada | Statistique Canada
Toronto Stock Exchange statistics

This table contains 25 series, with data for years 1956 - present (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (1 items: Canada ...), Toronto Stock Exchange Statistics (25 items: Standard and Poor's/Toronto Stock Exchange Composite Index; high; Standard and Poor's/Toronto Stock Exchange Composite Index; close; Toronto Stock Exchange; oil and gas; closing quotations; Standard and Poor's/Toronto Stock Exchange Composite Index; low ...).

Organization: Statistics Canada | Statistique Canada
Bank of Canada, assets and liabilities, average of Wednesdays

This table contains 29 series, with data starting from 1953 (not all combinations necessarily have data for all years). This table contains data described by the following dimensions (Not all combinations are available): Geography (1 items: Canada ...), Assets and liabilities (29 items: Total assets; Total; Government of Canada; bonds; Total; Government of Canada; direct and guaranteed securities; Government of Canada; Treasury Bills ...).

Organization: Statistics Canada | Statistique Canada
Interprovincial migration by first official language spoken and geography for interprovincial migrants aged 5 years and over, 1971 to 2021

Migration between provinces and territories (numbers and rates for in-migration, out-migration and net migration) by first official language spoken from 1971 to 2021. These data are based on the Census of Population and the 2011 National Household Survey.<br>

Organization: Statistics Canada | Statistique Canada
Indigenous Justice Strategy

In consultation and cooperation with Indigenous and provincial and territorial partners, Justice Canada is developing an Indigenous Justice Strategy to address systemic discrimination and the overrepresentation of Indigenous people in the justice system.
In the spirit of reconciliation, and out of respect for Indigenous rights to self-determination, Justice Canada recognizes that the development of an Indigenous Justice Strategy must be informed by First Nations, Inuit and Métis.
Working closely with Indigenous partners on the development of an Indigenous Justice Strategy will be an opportunity to inform and put in place effective and concrete measures, informed by the lived experiences of First Nations, Inuit and Métis, to improve Canada’s justice system.
The Indigenous Justice Strategy will be developed in five phases.


Organization: Department of Justice Canada | Ministère de la Justice Canada
Qualifying Notice - Lumakras

This Notice of Compliance with Conditions-Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Lumakras (sotorasib), control number 248435, for the indication of the treatment of adult patients with Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C-mutated locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have received at least one prior systemic therapy, qualifies to be considered for authorization in accordance with the NOC/c Guidance.

Organization: Health Canada | Santé Canada
Adoption of International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance: Q10: Pharmaceutical Quality System

Q10: Pharmaceutical Quality System. This guidance has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. The ICH Steering Committee has endorsed the final draft and recommended its adoption by the regulatory bodies of the European Union, Japan and USA.

Organization: Health Canada | Santé Canada
Experiences of Indigenous families in the family justice system: A literature review and perspectives from legal and frontline family justice professionals

The United Nations’ Declaration on the Rights of Indigenous Peoples (UNDRIP) asserts Indigenous peoples’ “right to access to and prompt decision through just and fair procedures for the resolution of conflicts and disputes” with “due consideration to the customs, traditions, rules and legal systems of the Indigenous peoples concerned and international human rights” (United Nations, 2007, art. 40). Aligning the Canadian justice system with UNDRIP requires a comprehensive understanding of the material and cultural needs of distinct Indigenous groups in Canada (Status and Non-status First Nations, Métis and Inuit) as well as of the processes and programs that can uphold Indigenous laws, heritage, languages and traditions not only within the colonial legal system, but also in the outcomes of legal proceedings.
This report aims to contribute to the understanding of the experiences of Indigenous families (specifically, unmarried or married couples with children) dealing with separation and divorce, who are going through the family justice system (FJS). This includes both identifying needs specific to Indigenous people going through the mainstream FJS and developing a better understanding of Indigenous approaches to resolving family conflicts. This preliminary information will help to identify specific challenges faced by and opportunities available for Indigenous families going through separation and divorce, and those who work with them. The research can inform future efforts to respond more effectively to the needs of Indigenous families and communities, as well as opportunities to welcome more effectively the gifts of Indigenous Knowledge Keepers through subsequent policy development, consultation, and research activities in relation to family law and family justice.

Organization: Department of Justice Canada | Ministère de la Justice Canada
HUMA committee briefing binder: Appearance of Minister of Employment, Workforce Development and Disability Inclusion – May 30, 2023

Appearance by the Minister of Minister of Employment, Workforce Development and Disability Inclusion, Carla Qualtrough, before the Standing Committee on Human Resources, Skills and Social Development and the Status of Persons with Disabilities (HUMA) – Main Estimates 2023 to 2024 and Supplementary Estimates (C), 2022 to 2023 – May 30, 2023

Organization: Employment and Social Development Canada | Emploi et Développement social Canada
Qualifying Notice - Veklury

This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Veklury (remdesivir), Control Number 240551, for the indication of "treatment of coronavirus disease 2019 (COVID-19) in adults and adolescents (aged 12 years and older with body weight at least 40 kg) with pneumonia requiring supplemental oxygen", qualifies to be considered for authorization in accordance with the NOC/c Guidance. In light of the public health emergency caused by the COVID-19 pandemic and because there are no currently approved therapeutic options, Health Canada is prepared to grant, on exceptional basis, flexibility in the application of the NOC/c Guidance and allow conditions for both the safety and quality profile of VEKLURY.

Organization: Health Canada | Santé Canada
Qualifying notice for Tepadina

This Notice of Compliance with Conditions-Qualifying Notice (NOC/c-QN) is to advise you that information submitted in support of the New Drug Submission for Tepadina (thiotepa), control number 168816, for the indication in combination with other chemotherapeutic products as part of a high-dose chemotherapy (HDCT) consolidation regimen followed by autologous stem cell transplantation (ASCT) for adult patients with central nervous system (CNS) lymphoma, qualifies to be considered for authorization under the Notice of Compliance with Conditions (NOC/c) Policy.

Organization: Health Canada | Santé Canada
Qualifying notice for Tepmetko

This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Tepmetko (tepotinib), Control Number 242300, for the indication of the treatment of adult patients with locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition (MET) tyrosine kinase receptor exon 14 skipping alterations, qualifies to be considered for authorization in accordance with the NOC/c Guidance

Organization: Health Canada | Santé Canada
Qualifying notice: Pemazyre

This Notice of Compliance with Conditions-Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Pemazyre (pemigatinib), control number 242569, indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement, qualifies to be considered for authorization in accordance with the NOC/c Guidance.

Organization: Health Canada | Santé Canada
Qualifying notice: Truseltiq

This Notice of Compliance with Conditions-Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Truseltiq (infigratinib phosphate), control number 246904, for the indication of treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 fusion or other rearrangement, qualifies to be considered for authorization in accordance with the NOC/c Guidance.

Organization: Health Canada | Santé Canada
Qualifying notice: Zepzelca

This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the Supplemental New Drug Submission for Zepzelca (lurbinectedin), control number 247485, indicated for the treatment of adults with Stage III or metastatic small cell lung cancer (SCLC) who have progressed on or after platinum-containing therapy, qualifies to be considered for authorization in accordance with the NOC/c Guidance.

Organization: Health Canada | Santé Canada
Qualifying Notice for Gavreto

This Notice of Compliance with Conditions Qualifying Notice (NOC/c-QN), issued in accordance with the Health Canada Guidance Document: Notice of Compliance with Conditions (NOC/c), is to advise you that information submitted in support of the New Drug Submission for Gavreto (pralsetinib), Control Number 243731, for the indication of the treatment of adult patients with rearranged during transfection (RET) fusion-positive locally advanced unresectable or metastatic non-small cell lung cancer (NSCLC). 

Organization: Health Canada | Santé Canada
Classification of products under the Food and Drugs Act (F&DA)

The Food and Drugs Act (F&DA) and its regulations serve as a basis for the classification of drugs, devices, food, and cosmetics. The definitions of "food," "drug," "cosmetic" and "device" in section 2 of the F&DA, and the definition of "natural health product" (NHP) in section 1 of the Natural Health Products Regulations, are fundamental to the classification of these products.

Organization: Health Canada | Santé Canada
Draft guidance document profile: Canadian Module 1 Technical Implementation Guide for the Electronic Common Technical Document (eCTD) v4.0 Format

This is a technical document that provides instructions on how to implement the ICH Electronic Common Technical Document v4.0 (eCTD v4.0) specification for Health Canada Module 1 submission content. The information in this document is provided in a consistent manner with the ICH eCTD v4.0 Implementation Guide.

Organization: Health Canada | Santé Canada
Health Canada approves updates to Mifegymiso prescribing information: Ultrasound no longer mandatory

Health Canada is informing Canadians that the prescribing and patient information for Mifegymiso has been updated to reflect that an ultrasound is no longer required before the drug is prescribed. Mifegymiso is a combination product containing two drugs (mifepristone and misoprostol) that are taken in sequence for the medical termination of a pregnancy.

Organization: Health Canada | Santé Canada
Adoption of International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance

Q8, Q9 and Q10 Questions & Answers (R4). This guidance has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. The ICH Steering Committee has endorsed the final draft and recommended its adoption by the regulatory bodies of the European Union, Japan and USA.

Organization: Health Canada | Santé Canada
Adoption of International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance Document: Q9: Quality Risk Management

Q9: Quality Risk Management. This guidance has been developed by the appropriate ICH Expert Working Group and has been subject to consultation by the regulatory parties, in accordance with the ICH Process. The ICH Steering Committee has endorsed the final draft and recommended its adoption by the regulatory bodies of the European Union, Japan and USA.

Organization: Health Canada | Santé Canada
Canadian species index

The Canadian Environmental Sustainability Indicators (CESI) program provides data and information to track Canada's performance on key environmental sustainability issues. The Canadian species index represents the average percent change in the sizes of Canadian vertebrate species' populations since 1970. The index is an "average of trends", rather than a measure of change in the total number of animals: each species, whether it is common or rare, has the same effect on the index. The index reports general trends rather than progress towards desired levels. Animal wildlife populations depend on healthy habitats and can be negatively impacted by threats such as pollution or hunting. Trends in animal populations are a good proxy measure of overall trends in biodiversity and ecosystem health. Information is provided to Canadians in a number of formats including: static and interactive maps, charts and graphs, HTML and CSV data tables and downloadable reports. See the supplementary documentation for the data sources and details on how the data were collected and how the indicator was calculated.


Canadian Environmental Sustainability Indicators: https://www.canada.ca/environmental-indicators


Supplemental Information


Canadian Environmental Sustainability Indicators - Home page:

               https://www.canada.ca/environmental-indicators


               Supporting Projects: Canadian Environmental Sustainability Indicators (CESI)

Organization: Environment and Climate Change Canada | Environnement et Changement climatique Canada
Notice – Release of ICH S5(R3): Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility

Health Canada is pleased to announce the implementation of International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) Guidance S5(R3): Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility. 

Organization: Health Canada | Santé Canada
Notice of Amendment: Prescription Drug List (PDL): Epinephrine (topical solution)

The purpose of this Notice of Amendment is to notify that Health Canada will add Epinephrine topical solution for hemostasis when sold at a concentration equal to or greater than 1 mg/ml (1:1000) to the Prescription Drug List (PDL). Both the Human and the Veterinary parts of the PDL were revised.

Organization: Health Canada | Santé Canada
Notice of Amendment: Tramadol removed from the Prescription Drug List (PDL)

The purpose of this Notice of Amendment is to notify that Health Canada has removed tramadol from the Prescription Drug List (PDL) and added it to Schedule I of the Controlled Drugs and Substances Act (CDSA) and to the Narcotic Control Regulations (NCR). Both the Human and Veterinary parts of the PDL were revised.

Organization: Health Canada | Santé Canada
Notice to Stakeholders – Clarification of Requirements under the Food and Drug Regulations and the Controlled Drugs and Substances Act When Conducting Clinical Research with Psilocybin

Health Canada is issuing this notice to clinical trial sponsors to clarify the approach to clinical research with psilocybin. Health Canada recognizes that conducting clinical research (i.e., research carried out on humans) is a critical step in the generation of good quality evidence needed to better understand the potential health benefits and harms associated with the therapeutic use of psilocybin.

Organization: Health Canada | Santé Canada
Notice to stakeholders: Considerations regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP)

Health Canada is aware of the growing interest in the use of psilocybin, including psilocybin that occurs naturally in certain mushroom species, for potential therapeutic purposes. In response, Health Canada is issuing this notice to provide information on the use of psilocybin mushrooms in clinical trials or as a drug requested through the Special Access Program (SAP), and to emphasize the importance of drug quality and Good Manufacturing Practices (GMP).

Organization: Health Canada | Santé Canada
Notice: Clinical trials for medical devices and drugs relating to COVID-19 regulations

The Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations (Regulations) were published on March 2, 2022. They came into effect on February 27, 2022, following the repeal of Interim Order No. 2 respecting clinical trials for medical devices and drugs relating to COVID-19 (IO No. 2).

Organization: Health Canada | Santé Canada
Notice: Confirmation of the Mandatory use of the Regulatory Enrolment Process (REP) as of October 1, 2020

By way of this update, Health Products and Food Branch (HPFB) is reminding sponsors that the mandatory date for use of the Regulatory Enrolment Process (REP) and the Common Electronic Submissions Gateway (CESG) is October 1, 2020 applicable to pharmaceutical, biologic and radiopharmaceutical drugs for human use as well as disinfectants, pursuant to Part C, Division 1 and Division 8 of the Food and Drug Regulations.

Organization: Health Canada | Santé Canada
Ensuring predictability for COVID-19 clinical trials and proposal for clinical trials records retention: Notice to stakeholders

The purpose of this notice is to advise stakeholders that Health Canada is proposing to: maintain the flexibilities and regulatory oversight provided by the Interim order respecting clinical trials for medical devices and drugs relating to COVID-19 until at least the fall of 2021, and bring forward regulatory amendments that would allow the flexibilities under the Interim Order to continue after the fall of 2021

Organization: Health Canada | Santé Canada
Understanding family violence in diverse communities: What subject-matter experts think family law legal advisers should know

This report summarizes five thought papers written by subject-matter experts to assist family law legal advisers in identifying and responding to family violence in diverse communities. The thought papers focused on the following population groups: racialized groups; 2SLGBTQI+ individuals; Muslim communities; newcomers; and people with disabilities.

Organization: Department of Justice Canada | Ministère de la Justice Canada
Plans to expand or restructure business or organization or acquire other businesses or organizations over the next 12 months, first quarter of 2022

<p>Plans for the business or organization to expand or restructure, or to acquire or invest in other businesses or organizations in the next 12 months, by North American Industry Classification System (NAICS), business employment size, type of business, business activity and majority ownership, first quarter of 2022.<br>
</p>


Organization: Statistics Canada | Statistique Canada
Privacy Act Modernization

The Department of Justice Canada has been leading efforts to modernize the federal Privacy Act, which is a key piece of Canada’s legal framework for protecting privacy interests. As part of this work, Justice Canada undertook an initial engagement with Indigenous governments and organizations from spring 2020 to spring 2021 to learn how a modernized Privacy Act could better reflect the needs, expectations and perspectives of First Nations, Inuit and Métis. Justice Canada’s 2022 engagement with First Nations, Inuit and Métis partners built on several themes and questions identified in the Initial Report that relate to the Privacy Act’s foundational principles and rules that play a significant role in governing information sharing between federal public bodies and Indigenous peoples.

Organization: Department of Justice Canada | Ministère de la Justice Canada